Novel Drug-Based Neuroprotective Therapies for Glaucoma

Principal Investigator
Adriana Di Polo, PhD
University of Montreal Hospital Center (Canada)
Montreal, Québec, Canada
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2008 - September 30, 2010
Grant ID
G2008027
Co-Principal Investigator(s)
Christian Casanova, PhD, University of Montreal Hospital Center (Canada)
Goals
This study will investigate the clinical potential of galantamine, a member of the acetylcholinesterase family, for the treatment of glaucoma. The study may lead to more effective drug-based therapies for treatment, and provide insight for the design of small molecule neuroprotective compounds with high specificity and few side effects.
Summary
At present, there is no cure for glaucoma and the only treatment available is to lower intraocular pressure using drugs or surgery. A significant proportion of patients continue to have disease progression and vision loss despite successful reduction of eye pressure. Thus, current therapeutic strategies for glaucoma are insufficient and new approaches to slow disease progression are urgently needed. This study will investigate the clinical potential of galantamine, a member of the acetylcholinesterase family, for the treatment of glaucoma. Galantamine as neuroprotective therapy in glaucoma has several competitive advantages including: efficacy to delay retinal ganglion cell (RGC) degeneration in experimental glaucoma, clinical history for Alzheimer’s disease that could lead to rapid clinical start-up, good safety profile, and excellent drug pharmacokinetics. The researchers will determine whether galantamine can protect vision after sustained periods of ocular hypertension damage. They will also elucidate the mechanisms by which galantamine confers RGC neuroprotection in glaucoma.
Grants
Related Grants
National Glaucoma Research
The Genetics of Glaucoma in Individuals of Caucasian and African Ancestry
Active Dates
March 01, 2021 - February 28, 2026
Principal Investigator
Michael Hauser, PhD
The Genetics of Glaucoma in Individuals of Caucasian and African Ancestry
Active Dates
March 01, 2021 - February 28, 2026

Principal Investigator
Michael Hauser, PhD
National Glaucoma Research
Saving Sight: A Journey to Healing Without Scars
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Jennifer Fan Gaskin, FRANZCO
Saving Sight: A Journey to Healing Without Scars
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Jennifer Fan Gaskin, FRANZCO
National Glaucoma Research
IOP-Related Gene Responses in the Optic Nerve Head and Trabecular Meshwork
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Diana C. Lozano, PhD
IOP-Related Gene Responses in the Optic Nerve Head and Trabecular Meshwork
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Diana C. Lozano, PhD